Determination of Piribedil in Human Serum, Urine and Pharmaceutical Dosage Form by LC-DAD

A rapid, selective and sensitive reversed-phase liquid chromatographic (LC) method was developed for the determination of piribedil in human serum, urine and pharmaceutical dosage form. LC analysis was carried out using reversed-phase isocratic elution with a C₁₈ column and a mobile phase of 0.01 M...

Full description

Saved in:
Bibliographic Details
Published in:Chromatographia 2008-06, Vol.67 (11-12), p.905-910
Main Authors: Altiokka, Göksel, Can, Nafiz Ö, Aboul-Enein, Hassan Y
Format: Article
Language:English
Subjects:
Analysis
Analytical Chemistry
Biological and medical sciences
Chemistry
Chemistry and Materials Science
Chromatography
General pharmacology
Laboratory Medicine
Medical sciences
Original
Pharmacology. Drug treatments
Pharmacy
Proteomics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A rapid, selective and sensitive reversed-phase liquid chromatographic (LC) method was developed for the determination of piribedil in human serum, urine and pharmaceutical dosage form. LC analysis was carried out using reversed-phase isocratic elution with a C₁₈ column and a mobile phase of 0.01 M phosphate buffer-acetonitrile (50:50, v/v). The chromatograms showed good resolution and sensitivity with no interference of human serum and urine. Piribedil concentrations were determined using diode array detection at 240 nm. Sildenafil citrate was used as internal standard. The limit of quantification (LOQ) and limit of detection (LOD) concentrations were 107.2 and 321.6 pg mL⁻¹, 96.6 and 290.4 pg mL⁻¹, 161.7 and 53.9 pg mL⁻¹ for urine, serum and pharmaceutical dosage forms, respectively. The method was validated for its linearity, precision and accuracy and applied to the tablets, urine and human serum. In addition, the results were compared to those obtained from UV-spectrophotometry.
ISSN:0009-5893
1612-1112
DOI:10.1365/s10337-008-0626-2